15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Rocket Pharmaceuticals Inc, 4 rate it Buy or better, 1 sit at Hold, and 2 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $3.00 to $263.00 (about 87.7x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $45.43 sits 1123% above the current $3.71. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.41 next quarter toward $-1.30 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy457%
Hold114%
Sell229%
Strong Sell00%
Based on 7 analysts giving stock ratings to Rocket Pharmaceuticals Inc.
As of Sep, 4 of 7 firms rate RCKT a Buy (1 Hold, 2 Sell), the standing distribution of every covering firm's most recent active call.
RCKT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.41
Range $-0.45 – $-0.37 · 5 analysts · +8% YoY
Next period, 5 analysts expect Rocket Pharmaceuticals Inc to earn $-0.41 a share (range $-0.45 – $-0.37), versus $-0.38 a year earlier. Full-year consensus is $-0.11, growing to $-1.30 the year after.
REVENUE · NEXT QUARTER
$624.6K
Range $0 – $3.0M · 5 analysts
Revenue is expected to reach $624.6K (range $0 – $3.0M). Full-year consensus is $1.1M, rising to $11.2M next year.
Top analysts covering Rocket Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RCKT.
#1
Geulah Livshits
Chardan Capital · Rank #85
Buy
$11.00+196.1% to target
Overall win rate
46%
+ Follow
#2
Keay Nakae
Chardan Capital · Rank #89
Buy
$11.00+196.1% to target
Overall win rate
43%
+ Follow
#3
Josh Schimmer
Cantor Fitzgerald · Rank #162
Buy
$10.00+169.2% to target
Overall win rate
38%
+ Follow
#4
Greg Harrison
Scotiabank · Rank #179
Buy
$19.00+411.4% to target
Overall win rate
38%
+ Follow
#5
Gil Blum
Needham · Rank #340
Hold
No targeton RCKT
Overall win rate
26%
+ Follow
RCKT stock forecast FAQ
What is RCKT's average 12-month price target?+
The 7 analysts with a live target average $45.43 for Rocket Pharmaceuticals Inc over the next 12 months, ranging from a $263.00 high to a $3.00 low.
Is RCKT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 4 are Buy or Strong Buy, 1 are Hold, and 2 are Sell or Strong Sell.
What are the highest and lowest price targets for RCKT?+
The Street-high target is $263.00 (JP Morgan), and the Street-low is $3.00 (Goldman Sachs). The average of all 7 active targets is $45.43.
How many Wall Street analysts cover RCKT?+
7 analysts have an active rating on Rocket Pharmaceuticals Inc, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering RCKT?+
Among analysts who currently cover RCKT, Geulah Livshits of Chardan Capital has the strongest overall Quantellect track record (Rank #85). Their current call is Buy with a $11.00 target.
What is Rocket Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.41 per share (range $-0.45 – $-0.37) across 5 analysts. Full-year EPS is projected at $-0.11, rising to $-1.30 the following year.
How much revenue is Rocket Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $624.6K (range $0 – $3.0M). Full-year revenue is projected at $1.1M, growing to $11.2M next year.
Have analysts been upgrading or downgrading RCKT lately?+
As of Sep, 4 of 7 firms rate RCKT a Buy (1 Hold, 2 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RCKT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
